Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07183852 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma

Study acronym: GoTIL-01
StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Mar 2026 to Jan 2027v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Vastra Gotaland Region
139 trials monitored
See 11 trials at risk
Melanoma
1,092 trials monitored
See 60 trials at risk
The purpose of this study is to evaluate the feasibility, safety and tolerability of locoregional or systemic administration of autologous tumor infiltrating lymphocytes in patients with metastatic melanoma
Trial Details
NCT Number NCT07183852
Lead Sponsor Vastra Gotaland Region
Conditions
(from sponsor)		 Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma
Related terms Melanoma, Uveal Melanoma
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov